Inclusion Criteria:  Diagnosed with acute MI, either STEMI or NSTEMI, according to the fourth universal definition of MI (Thygesen et al. 2019), disease onset within 7 days. Previously diagnosed with type2 diabetes mellitus, newly diagnosed type2 diabetes according to ADA criteria or glucose intolerance. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and the protocol.  Exclusion Criteria:  Patients diagnosed with Type 1 Diabetes Mellitus. Patients with renal dysfunction. (GFR<90mmol/L). Patients who have recently undergone immunosuppressive therapy. Patients with a history of recurrent urinary tract infections. Patients who are known to be allergic to SGLT-2 inhibitors. Patients who are hemodynamically unstable. Chronic symptomatic heart failure within the last year and known reduced ejection fraction (LVEF≤40 %), documented before the current MI hospitalization. Severe hepatic impairment (Child-Pugh class C) at the time of inclusion into the trial. Any other non cardiovascular diseases, such as active malignancy requiring treatment at the time of screening or with a life expectancy of fewer than two years based on the investigator´s clinical judgment. Currently on treatment with a sodium-glucose co-transporter 2 inhibitor (SGLT2-inhibitor).